Caris Life Sciences (CAI) Return on Capital Employed (2025 - 2026)

Caris Life Sciences (CAI) recorded quarterly Return on Capital Employed of 10.83% in Q1 2026, up 122.84% quarter-over-quarter from 4.86% in Q4 2025.

Caris Life Sciences (CAI) Return on Capital Employed (2025 - 2026) Analysis & Trends

Caris Life Sciences' Return on Capital Employed history runs 2 years deep, the most recent figure standing at 10.83% for Q1 2026.

In Q1 2026, Return on Capital Employed changed N/A year-over-year to 10.83%; the TTM figure through Mar 2026 stood at 10.83% (changed N/A YoY), while the FY2025 annual figure was 7.43%, changed N/A from the prior year.
Return on Capital Employed was 10.83% for Q1 2026 at Caris Life Sciences, up from 4.86% in the prior quarter.
In the past five years, Return on Capital Employed ranged from a high of 10.83% in Q1 2026 to a low of 9.09% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	450.31%
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	51.73%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-107.40%
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	21.10%
9	Abivax	91.96 Bn	91.96 Bn	-	-50.43%
10	Caris Life Sciences	5.22 Bn	4.40 Bn	171.13 Mn	10.83%

Download Data